Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.

[1]  K. M. Pettersen,et al.  Hepatitis C Virus Infection as a Traumatic Experience , 2014, PloS one.

[2]  M. Stepanova,et al.  Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens , 2014, Alimentary pharmacology & therapeutics.

[3]  L. Sticchi,et al.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. , 2014, World journal of gastroenterology.

[4]  L. Gerber,et al.  Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  E. Verna.  Hepatitis viruses and liver transplantation: evolving trends in antiviral management. , 2014, Clinics in liver disease.

[6]  O. Weiland,et al.  Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. , 2014, Journal of hepatology.

[7]  M. Stepanova,et al.  Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens , 2014, Hepatology.

[8]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[9]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[10]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[11]  M. Stepanova,et al.  Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). , 2014, Journal of hepatology.

[12]  W. Kim,et al.  The impact of hepatitis C burden: an evidence‐based approach , 2014, Alimentary pharmacology & therapeutics.

[13]  M. Stepanova,et al.  Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C , 2013, Journal of viral hepatitis.

[14]  A. Moorman,et al.  Hepatitis C in the United States. , 2013, The New England journal of medicine.

[15]  D. Alsop,et al.  Reply to: “Neuroinflammation in HCV-infection – Peril or protection?”: Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition , 2012 .

[16]  R. Lenkinski,et al.  Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. , 2012, Journal of hepatology.

[17]  D. Forton.  Hepatitis C treatment--clearing the mind. , 2012, Journal of hepatology.

[18]  U. Iloeje,et al.  Absenteeism and productivity among employees being treated for hepatitis C. , 2011, The American journal of managed care.

[19]  G. L’italien,et al.  The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities , 2011, Journal of medical economics.

[20]  A. Alberti.  Impact of a sustained virological response on the long‐term outcome of hepatitis C , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[21]  L. Dal Maso,et al.  Manifestations of chronic hepatitis C virus infection beyond the liver. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  N. Kleinman,et al.  The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs , 2010, Hepatology.

[23]  R. Fontana,et al.  Changes in quality of life and sexual health are associated with low‐dose peginterferon therapy and disease progression in patients with chronic hepatitis C , 2010, Alimentary pharmacology & therapeutics.

[24]  G. Davis,et al.  The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers , 2010, Current gastroenterology reports.

[25]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[26]  R. Bressan,et al.  Neuropsychological function in patients with chronic hepatitis C , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[27]  Z. Younossi,et al.  Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection , 2007, Digestive Diseases and Sciences.

[28]  Z. Younossi,et al.  The effects of HCV infection and management on health‐related quality of life , 2007, Hepatology.

[29]  R. Fontana,et al.  Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. , 2007, Journal of hepatology.

[30]  Z. Younossi,et al.  Health-related quality of life (HRQL) in chronic liver disease. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[31]  R. Fontana,et al.  Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. , 2005, Journal of hepatology.

[32]  J. Allsop,et al.  A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. , 2005, AIDS.

[33]  R. Hays,et al.  Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment , 2005, Hepatology.

[34]  J. Ware,et al.  Health‐related quality of life in chronic hepatitis C: Impact of disease and treatment response , 1999, Hepatology.

[35]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[36]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[37]  H. Popper.  American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .

[38]  R. Bressan,et al.  High frequency of unrecognized mental disorders in HCV-infected patients. , 2008, General hospital psychiatry.

[39]  J. Ware,et al.  Interpreting SF&-36 summary health measures: A response , 2004, Quality of Life Research.

[40]  I. Yang,et al.  The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. , 2001, Journal of hepatology.